Welcome to our dedicated page for Outlook Therapeutics SEC filings (Ticker: OTLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outlook Therapeutics, Inc. filings document material events for a Nasdaq-listed biopharmaceutical company focused on ONS-5010/LYTENAVA for wet AMD and other retina-disease applications. The company’s 8-K disclosures cover FDA-related communications for its biologics license application, including Complete Response Letter follow-up, Type A meeting activity and formal dispute-resolution matters.
Regulatory filings also describe capital-structure activity involving common stock, warrants, registered and unregistered securities, note financing and amendments to debt instruments. Governance records include shareholder voting results, board composition changes, proxy-related matters, Nasdaq-listed common stock information, exhibits and risk-factor or material-agreement disclosures tied to financing and regulatory developments.
Outlook Therapeutics, Inc. reported that the U.S. Food and Drug Administration issued a complete response letter to its biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab being developed to treat wet age-related macular degeneration (wet AMD). A complete response letter means the FDA has finished its review but has decided that the application cannot be approved in its current form. The company disclosed this development through a press release, which is included as an exhibit to the report.
Great Point Partners, LLC together with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl report beneficial ownership of 2,220,000 shares of Outlook Therapeutics, Inc. common stock, representing 4.99% of the outstanding shares based on 42,192,728 shares reported by the issuer. The holdings consist of warrants to purchase 2,220,000 shares, which are treated as beneficially owned but are subject to an exercise restriction (a Beneficial Ownership Cap) that prevents exercise if it would increase ownership above 9.99%.
The reporting persons disclose shared voting and dispositive power over the 2,220,000 shares and state the position is not held to influence control of the issuer. The filing is a joint Schedule 13G/A and includes a Joint Filing Agreement executed August 14, 2025.
Outlook Therapeutics, Inc. (OTLK) reports commercial availability of LYTENAVA (bevacizumab gamma) in Europe in fiscal 2025 and recognizes revenue when product is delivered to pharmaceutical wholesalers, with returns, rebates and administrative fees contractually applied. The company has 260,000,000 shares authorized and reported 43,479,051 shares issued and outstanding at June 30, 2025 versus 23,905,635 at September 30, 2024.
The filing details multiple financing transactions in 2025 including a public offering that generated net proceeds of $11,625,229, ATM capacity with $88,301,796 remaining as of June 30, 2025, and several warrant inducement transactions that produced net proceeds and resulted in mark-to-market and inducement charges (including $27,711,889 and $4,196,868 recorded for the nine months ended June 30, 2025). The company notes a March 2025 Note with conversion mechanics, high default interest (22% per annum) and potential dilution triggers. A securities class action is pending and a motion to dismiss is under review.
Outlook Therapeutics, Inc. furnished a press release announcing its financial results for the third fiscal quarter ended June 30, 2025. The company released these results through a press release dated August 14, 2025, which is attached as Exhibit 99.1. The disclosure is furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
Outlook Therapeutics, Inc. Schedule 13G/A reports that Tang Capital entities and Kevin Tang collectively beneficially own 1,500,000 shares of the company's common stock, representing 3.4% of the outstanding class on a diluted basis. Those shares are currently issuable upon exercise of warrants held by Tang Capital Partners, LP, and the filing states the percentages are based on 43,692,728 shares (42,192,728 outstanding plus 1,500,000 issuable warrants). TCP's warrants are exercisable for one share each but include a beneficial ownership cap preventing exercise that would increase ownership above 9.99% unless TCP provides notice to increase to a maximum of 19.99% with a 61-day delay. Voting and dispositive power over the shares is shared among Tang Capital Management, Tang Capital Partners, LP and Kevin Tang.